STAT+: Pharmalittle: We’re reading about biotech investors’ mood, a former FDA head’s confidence, and more
Biotech investors are becoming less concerned about the political risks associated with the Make America Healthy Again movement, as recent changes at the FDA have improved sentiment in the industry. Former FDA Commissioner David Kessler expresses optimism about the agency's future under new acting commissioner Kyle Diamantas, despite his non-medical background.
For a professional tracking biotech and healthtech, the key takeaway is that the political risks associated with the "Make America Healthy Again" movement are diminishing in importance for biotech investors, now overshadowed by concerns like interest rates, clinical data, and earnings. This shift, along with recent changes at the FDA, suggests a more favorable regulatory environment for drug companies, potentially signaling a more stable period for investments in the sector.